Industries > Pharma > Asthma & COPD Market Report 2016-2026

Asthma & COPD Market Report 2016-2026

Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs

PUBLISHED: 25 October 2016
PAGES: 314
PRODUCT CODE: PHA0149
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0149 Categories: ,

Visiongain’s comprehensive new 313 page report reveals that the global asthma & COPD market will achieve revenues of $33.2bn in 2016.

Are you involved in the asthma & COPD market or intend to be? If so, then you must read this report.
It’s vital that you keep your knowledge up to date. You need this report.

Market scope: Asthma & COPD are among the most common and debilitating respiratory conditions. Drugs for the treatment of these conditions fall into 3 main categories: Bronchodilator monotherapy, anti-inflammatory drugs and combination drugs. Visiongain assesses how these three submarkets and the 12 largest national markets will evolve over the forecast period.The competitive landscape is further illustrated with examination of the 7 market leading manufacturers.

The asthma & COPD Market 2016-2026 report responds to your need for definitive market data:

• Where are the asthma & COPD market opportunities?
– 248 tables, charts, and graphs reveal market data allowing you to target your strategy more effectively

• When will the asthma & COPD market grow?
– Global, regional and asthma & COPD submarket forecasts and analysis from 2016-2026 illustrate the market progression

• Which asthma & COPD submarkets will flourish from 2016-2026?
– Individual application forecasts and analysis demonstrate the prospects
• Combination drugs forecast 2016-2026
• Anti-inflammatory drugs forecast 2016-2026
– Corticosteroids forecast 2016-2026
– Anti-Leukotrienes forecast 2016-2026
– Monoclonal antibodies forecast 2016-2026
– Other anti-inflammatories forecast 2016-2026
• Bronchodilator monotherapy forecast 2016-2026
– Short-acting beta2-agonist (SABAs) forecast 2016-2026
– Long-acting beta2-agonist (LABAs) forecast 2016-2026
– Anticholinergics forecast 2016-2026

• Where are the regional asthma & COPD market opportunities from 2016-2026?
– Focused regional forecasts and analysis explore the future opportunities
– US forecast 2016-2026,
– China forecast 2016-2026
– Japan forecast 2016-2026
– India forecast 2016-2026
– Germany forecast 2016-2026
– UK forecast 2016-2026
– France forecast 2016-2026
– Mexico forecast 2016-2026
– Brazil forecast 2016-2026
– Russia forecast 2016-2026

• What are the factors influencing asthma & COPD market dynamics?
– SWOT / Porter’s Five Forces analysis explores the factors.
– Research and development (R&D) strategy
– Technological issues and constraints.
– Supply and demand dynamics
– Competition from new product types
– Increasing specialisation by leading players
– Advances in product quality

• Who are the leading asthma & COPD companies?
– Examine competitive positioning, product portfolios, R&D activity, M&A activity, and future outlook.
– GSK
– Boehringer Ingelheim
– AstraZeneca
– Merck & Co. Inc (Merck)
– Novartis
– Roche
– Teva

Asthma & COPD Market Report 2016-2026

• Who should read this report?
– Anyone within the asthma & COPD value chain, including
– CEO’s
– COO’s
– CIO’s
– Business development managers
– Marketing managers
– Suppliers
– Technologists
– Investors
– Banks
– Government agencies
– Contractors

Get our report today Asthma & COPD Market Report 2016-2026: Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs. Avoid missing out – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Asthma & COPD Market Report 2016-2026


Download sample pages

Complete the form below to download your free sample pages for Asthma & COPD Market Report 2016-2026


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories